Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
225.8 EUR | -1.40% |
|
-.--% | -.--% |
Jun. 24 | Tecan Appoints Mukta Acharya as Head of the Life Sciences Business Division, Effective from August 1, 2024 | CI |
Apr. 18 | Tecan Group Approves Dividend, Payable on April 24, 2024 | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 32.03 and 27.34 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.52 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Office Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 4.44B | - | ||
+8.80% | 7.75B | B- | ||
+3.70% | 3.25B | - | ||
+13.70% | 2.23B | - | ||
+8.81% | 1.02B | C+ | ||
+11.24% | 968M | - | ||
-38.88% | 928M | - | ||
-32.43% | 661M | - | ||
-59.04% | 645M | - | ||
-32.78% | 596M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TECN Stock
- TEN Stock
- Ratings Tecan Group AG